Researchers have used the latest in RNA and machine learning technologies to develop an accurate liposarcoma test
February 10, 2021
Elsevier
Philadelphia, February 4, 2021 Researchers have leveraged the latest advances in RNA technology and machine learning methods to develop a gene panel test that allows for highly accurate diagnosis of the most common types of liposarcoma. It quickly and reliably distinguishes benign lipomas from liposarcomas and can be performed in laboratories at a lower cost than current gold standard tests.
The Journal of Molecular Diagnostics, published by Elsevier. Liposarcomas are a type of malignant cancer that is difficult to diagnose because, even under a microscope, it is hard to differentiate liposarcomas from benign tumors or other types of cancer that need different treatments, explains lead investigator Torsten Owen Nielsen, MD, PhD, Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British
Gene panel test enables highly accurate diagnosis of liposarcomas
Researchers have leveraged the latest advances in RNA technology and machine learning methods to develop a gene panel test that allows for highly accurate diagnosis of the most common types of liposarcoma. It quickly and reliably distinguishes benign lipomas from liposarcomas and can be performed in laboratories at a lower cost than current gold standard tests. The new assay is described in
The Journal of Molecular Diagnosis, published by Elsevier.
Liposarcomas are a type of malignant cancer that is difficult to diagnose because, even under a microscope, it is hard to differentiate liposarcomas from benign tumors or other types of cancer that need different treatments. Many liposarcomas look like their benign and relatively common counterparts, lipomas. Diagnostic delay and uncertainty cause severe stress for patients, and misdiagnosis can have many consequences including delayed or inadequate treatment or unnece